Kerr Douglas sold $41K of DYN
Kerr Douglas (Chief Medical Officer) sold 1,556 shares of Dyne Therapeutics, Inc. (DYN) at $26.28 on 2026-08-13 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific open-market sale size, price, and that it was executed under a pre-arranged 10b5-1 plan.
Market read
Traders may monitor insider activity for sentiment, but this filing alone does not provide new operational or financial guidance.
What to watch
The filing does not disclose reasons for the sale, and the post-transaction holdings remain substantial (167,599 shares), limiting inference about long-term conviction.
Background
The article is an SEC Form 4 insider transaction disclosure for Dyne Therapeutics, Inc.
Ticker impact
Dyne Therapeutics CMO Kerr Douglas sold 1,556 shares in an open-market transaction at $26.2800 on 2026-08-13 under a 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around insider selling.
Form 4 reports the sale details and confirms a pre-arranged 10b5-1 plan, which typically reduces interpretive signal versus discretionary selling.
Market effects
No direct sector read-through; this is company-specific insider transaction reporting.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect routine liquidity rather than negative expectations, so any bearish interpretation may be overstated.
Key entities
- issuerDyne Therapeutics, Inc.
Subject of the Form 4 insider sale disclosure (DYN).
- insiderKerr Douglas
Chief Medical Officer who sold 1,556 shares under a 10b5-1 plan.
